Prathap Madeswaraguptha

Prathap Madeswaraguptha

Auto-generated profile, based on publicly available information

Prathap Madeswaraguptha

Amity Institute of Pharmacy, Amity University, Gwalior, Madhya Pradesh, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2026 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
MKMonika Kaushik
Monika Kaushik
MPMrugendra Potdar
Mrugendra Potdar
PMPrathap Madeswaraguptha
Prathap Madeswaraguptha
MVMurugesan Vanangamudi
Murugesan Vanangamudi
MAMd Abubakar
Md Abubakar
Sachchida Nand RaiSachchida Nand Rai
Sachchida Nand Rai
Introduction: Mitochondria play an important role in maintaining redox balance, energy, calcium, and the viability of neurons. The mitochondrial dysfunction is one of the primary sources of glial activation and dopaminergic neuron loss in Parkinson's disease (PD). The key biochemical elements of the pathogenesis of PD include impaired oxidative phosphorylation, elevated generation of reactive oxygen species (ROS), and impaired mitophagy. Methods: This review is a synthesis and stringent evaluation of recent experimental, clinical and genetic studies relating mitochondrial dysfunction and Parkinson's disease (PD). We examined information on bioenergetics, mitochondrial dynamics, calcium homeostasis, and interactions between neurons and glia. The molecular and therapeutic importance of therapies, such as mitophagy modulators, bioenergetic enhancers, and mitochondrial antioxidants, was investigated. The absence of Complex I, excess ROS, mitochondrial DNA damage, and nonfunctioning fusionfission cycles leads to neurodegeneration. The glial metabolic abnormalities worsen the oxidative stress and neuroinflammation, weakening the support of the neurons. The effects of impaired mitophagy are the accumulation of dysfunctional mitochondria, and the effects of calcium overload disrupt energy metabolism. Neuroprotective effects of such substances as spermidine, urolithin A, resveratrol, αlipoic acid, MitoQ, SkQ1, or CoQ10 have been shown using preclinical research. Sacrifices such as exercising and proper dieting enable the mitochondria to perform better and become stronger. Discussion: Mitochondrial dysfunction enhances the progression of PD through oxidative stress, bioenergetic breakdown, and inflammatory signalling. Attention to these related systems is an entire way to alter the direction of a disease. Conclusion: PD can be treated using an increase in mitochondrial quality control, redox regulation, and metabolic efficiency. Continued studies in the framework of precision medicine are required to validate the safety and effectiveness of mitochondrial-targeted medications.

28 January 2022 in Current Pharmaceutical Analysis
Verified
Journal Article
Closed access
PDF file
VSVijayaraj Surendran
Vijayaraj Surendran
NPNarahari N. Palei
Narahari N. Palei
MVMurugesan Vanangamudi
Murugesan Vanangamudi
PMPrathap Madheswaragupta
Prathap Madheswaragupta
Background: Hybrid polymeric materials have been in research focus owing to their outstanding progression in drug targeting. A new Quality by Design approach by RP-HPLC was developed and validated for the estimation of hybrid polymeric nanoparticles of Ritonavir in rat plasma. Objective: The main objective of the present study was to develop and validate a simple, robust, and accurate method by QbD approach for the detection of hybrid polymeric nanoparticles of Ritonavir (RTV) in plasma. Methods: The mobile phase consisting of a mixture of Acetonitrile: HPLC grade water (60:40 v/v), 1.0 ml/min flow rate and UV detection at 240 nm. Critical Analytical Attributes (CAAs) were screened and selected by Taguchi orthogonal array model. Box-Behnken's three-level, the 3- factorial design, was employed to create and analyze a "Design Space" (DoE). This design was statistically analyzed by ANOVA, contour-plot, and 3D response surfaces plots, which demonstrated that the model was statistically significant. The developed method was validated as per the ICH guidelines Q2 (R1). Results: The developed method showed excellent linearity between 100 and 600 ng/mL with good regression (R2>0.998), LOD (10 ng/mL) and LOQ (30 ng/mL). The validation results of the tested parameters were found within the acceptable limit. Conclusion: From the study, it was concluded that QbD driven bioanalytical method is suitable for the in-vitro and in-vivo estimation of RTV from bulk as well as from hybrid polymeric nanoparticles formulation.

21 February 2024 in Macromolecular Symposia
Verified
Journal Article
Closed access
VSVijayaraj Surendran
Vijayaraj Surendran
PMPrathap Madheswaraguptha
Prathap Madheswaraguptha
PRParameshwar Ravula
Parameshwar Ravula
PRPonnusamy Rajavel
Ponnusamy Rajavel
EAElphine Prabahar A
Elphine Prabahar A

1 July 2025 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
PGPrathap Madeswara Guptha
Prathap Madeswara Guptha
NPNarahari Narayan Palei
Narahari Narayan Palei
MVMurugesan Vanangamudi
Murugesan Vanangamudi
SVSurendran Vijayaraj
Surendran Vijayaraj
BMBibhash Chandra Mohanta
Bibhash Chandra Mohanta
Background: Ritonavir (RTV) is an antiviral drug that prevents human immunodeficiency virus (HIV). However, it has low bioavailability, which can be improved with the assistance of Solid Lipid Nanoparticles (SLNs). Objective: The present work aimed to formulate and optimize RTV-loaded SLNs using Box–Behnken design and evaluate the permeability coefficient using ex vivo permeation studies. Methods: RTV-SLNs were prepared using the ultrasonication technique. The SLN formulation was optimized based on particle size, % entrapment efficiency, and % cumulative drug release using response surface methodology resulting from Box-Behnken design. The Fourier-Transform Infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and transmission Electron Microscopy (TEM) studies were carried out for the characterization of optimized SLN formulation. Ex vivo permeation studies were also performed using chicken ileum. Results: The optimized RTV-SLNs had a particle size of 270.34 nm, polydispersity index of 0.157, and zeta potential of -25.2 mV. The % entrapment efficiency and % cumulative drug release were found to be 94.33% and 67.13%, respectively. The FT-IR study revealed that SLNs showed no significant interactions between the drug and lipid in the formulation. The % crystalline index of the RTV-loaded SLN formulation was found to be 44.31% compared to the reference value of 100% for lipids. TEM analysis showed spherical nanoparticles that were uniform in shape. The release kinetics data demonstrated the drug release behavior, followed by the Korsmeyer-Peppas model, and suggested that the release from SLNs followed the non-fiction diffusion. The permeability coefficient of optimized SLN formulation was found to be significantly (p < 0.05) more compared to free RTV suspension. The enhancement ratio results suggested that RTV-SLNs permeated significantly (p < 0.05) faster (approximately 3.5 times) as compared to free RTV suspension. Conclusion: The optimized RTV-SLNs could be a promising carrier for improving the oral bioavailability of RTV.

25 December 2023 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
NPNarahari Narayan Palei
Narahari Narayan Palei
BMBibhash Chandra Mohanta
Bibhash Chandra Mohanta
JRJAYARAMAN RAJANGAM
JAYARAMAN RAJANGAM
PMPrathap Madheswaragupta
Prathap Madheswaragupta
Olmesartan medoxomil (OLM) is a low bioavailability antihypertensive drug. This study aimed to prepare and optimize an OLM niosomal gel and investigate drug permeation via a chicken buccal pouch. OLM-loaded niosome were prepared using a film hydration technique. The vesicle size, zeta potential, entrapment efficiency, and percentage cumulative drug release of niosome were evaluated. The niosomes were incorporated into a Carbopol 974P (1.5% w/v) gel, and the drug permeability of the niosomal gel was evaluated. The formulations of the niosomal gel were optimized using the Box-Behnken design. The optimized formulation was further characterized by transmission electron microscopy (TEM) and Fourier transform infrared radiation analysis. The particle size and zeta potential of the optimized niosomal formulations were 296.4 nm and -38.4 mV, respectively. Based on TEM analysis, the niosomes were found to be spherical in shape. The permeability, flux, and permeability coefficient of the optimized niosomal gel were 0.507 mg/cm2, 0.083 mg/cm2 × hour, and 041 cm/hour, respectively. Histopathological evaluation revealed that the niosomal gel had better permeability than the OLM gel. Based on the results of the OLM niosomal gel, it can be concluded that the formulation can be beneficial in increasing bioavailability, resulting in better therapeutic efficacy.

1 May 2025 in Current Cancer Therapy Reviews
Verified
Journal Article
Closed access
PDF file
MVMurugesan Vanangamudi
Murugesan Vanangamudi
MKMonika Kaushik
Monika Kaushik
PMPrathap Madeswaraguptha
Prathap Madeswaraguptha
VSVijayaraj Surendran
Vijayaraj Surendran
PGPawan Kumar Gupta
Pawan Kumar Gupta
Targeted protein degradation is a rapidly expanding area that offers hope for novel approaches to combat drug resistance. The creation of heterobifunctional proteolysis-targeting chimeras [PROTACs], a new group of pharmaceutical compounds, has made TPD a useful method for completely getting rid of harmful proteins using regular small-molecule inhibitors. A big plus is that PROTACs can target multi-domain proteins that cannot be broken down. This is the case, particularly for proteins lacking a conserved interaction surface for small-molecule ligands SMIs and featuring smooth surfaces. Poor oral bioavailability and pharmacokinetic PK and ADMET absorption, distribution, metabolism, excretion, and toxicity characteristics are among the long-term issues with traditional PROTACs. Their larger size and more complex structure set them apart from other smallmolecule inhibitors, which is why they are so effective. Clinical studies have been conducted on a plethora of PROTAC compounds in the past 20 years, all with the goal of inducing the degradation of targets relevant to cancer. In this article, we closely examine the major developments and recent advancements in PROTAC technology. We seek to summarize and fully assess PROTAC-based targeted protein degradation studies on "undruggable" targets. Discussing their molecular structure, action mechanism, design concepts, development benefits, and obstacles will help to illustrate the significance of developing highly successful PROTAC-based techniques in treating many illnesses, including cancer treatment resistance.